The PLAC® Activity Test is a strong and independent risk factor

regards The FDA cleared PLAC Activity Test showed a strong association with CHD events* as compared to traditional risk factors even after adjusting for age, gender, race, diabetes and smoking status. Only complex clinical conditions such as diabetes and smoking status demonstrated greater hazard ratios for CHD events.  

Effectiveness of the PLAC Activity Test has been demonstrated across multiple clinical trials and patient populations.

  • The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events (Figure 1)
  • A PLAC Activity Test result above 225 nmol/min/mL identifies patients at increased risk for CHD events across patient type and population (Figure 2)
  • Absolute risk of CHD events is 2.1 times greater with a positive PLAC Test (Figure 2)
Lp-PLA2 Activity and CHD Risk4
risk ratio
*Fatal and non-fatal events
Figure 2
Risk for CHD Event Rates by Patient Type5
Increased absolute risk for certain sub-populations
Figure 3

high-225-low (1)

The PLAC® Activity Test incorporates a validated, easy-to-use cut point of 225 nmol/min/mL.


The PLAC Activity Test provides physicians with additional prognostic information previously unavailable with traditional risk factors. LEARN MORE


The PLAC Activity Test offers enhanced cardiovascular risk assessment from your laboratory. LEARN MORE